NewcelX Ltd. filings associated with NLSPW document foreign-issuer current reports, registration-statement references, material-event disclosures, shareholder voting matters, capital-structure items, governance matters, and clinical or regulatory updates. The records reflect the company’s public reporting transition from NLS Pharmaceutics-related securities to NewcelX as a Swiss clinical-stage regenerative medicine issuer.
Recent Form 6-K reports furnish press releases and investor presentations covering stem-cell-derived therapies, the NCEL-101 Type 1 Diabetes program, a stem-cell-derived islet replacement platform, and a strategic collaboration involving targeted immune modulation. The filing record also includes security-structure and registration disclosures, including references to Form F-3 registration statements and Form 20-F foreign private issuer reporting status.
League Jinn Sarl and Julien Ruggieri report beneficial ownership of 1,316,267 NewcelX Ltd. common shares, representing 25.3% of the class. Their position includes 1,104,568 common shares plus warrants for 20,791 shares at $2.75 and 190,908 shares at $3.025, all exercisable within 60 days of April 27, 2026, subject to a 9.99% beneficial ownership cap.
The stake is based on 5,345,184 common shares outstanding as of April 29, 2026. The holding was built through a 2024 private placement in NLS Pharmaceutics (NewcelX’s predecessor), equity received in the Kadimastem merger, and an April 2026 private placement where the investor bought additional shares and warrants with personal funds.
League Jinn Sarl and Julien Ruggieri report beneficial ownership of 1,316,267 NewcelX Ltd. common shares, representing 25.3% of the class. Their position includes 1,104,568 common shares plus warrants for 20,791 shares at $2.75 and 190,908 shares at $3.025, all exercisable within 60 days of April 27, 2026, subject to a 9.99% beneficial ownership cap.
The stake is based on 5,345,184 common shares outstanding as of April 29, 2026. The holding was built through a 2024 private placement in NLS Pharmaceutics (NewcelX’s predecessor), equity received in the Kadimastem merger, and an April 2026 private placement where the investor bought additional shares and warrants with personal funds.
NewcelX Ltd. reported a 2025 net loss of $8.3 million, driven largely by $5.7 million of non-cash finance expenses linked to convertible instruments that were converted before completion of its merger. Operating loss was $2.6 million, reflecting research and development and general and administrative spending typical for a clinical-stage company.
Cash and cash equivalents were $2.2 million as of December 31, 2025, and the balance sheet shows total assets of $11.4 million and equity of $7.3 million, with the company describing itself as substantially debt free. In April 2026, NewcelX completed a $1.35 million private placement with up to approximately $2.0 million of additional potential warrant proceeds and retains access to a $25 million equity line of credit. The company is prioritizing development of its NCEL-101 stem-cell-derived therapy for Type 1 Diabetes in collaboration with Eledon Pharmaceuticals and continues to advance its broader cell therapy pipeline, including AstroRx for ALS and DOXA for narcolepsy and other CNS indications.
NewcelX Ltd. reported a 2025 net loss of $8.3 million, driven largely by $5.7 million of non-cash finance expenses linked to convertible instruments that were converted before completion of its merger. Operating loss was $2.6 million, reflecting research and development and general and administrative spending typical for a clinical-stage company.
Cash and cash equivalents were $2.2 million as of December 31, 2025, and the balance sheet shows total assets of $11.4 million and equity of $7.3 million, with the company describing itself as substantially debt free. In April 2026, NewcelX completed a $1.35 million private placement with up to approximately $2.0 million of additional potential warrant proceeds and retains access to a $25 million equity line of credit. The company is prioritizing development of its NCEL-101 stem-cell-derived therapy for Type 1 Diabetes in collaboration with Eledon Pharmaceuticals and continues to advance its broader cell therapy pipeline, including AstroRx for ALS and DOXA for narcolepsy and other CNS indications.
NewcelX Ltd. director Samuel Olivier reported open-market purchases of both common shares and warrants. He bought 81,818 common shares of NewcelX at $2.75 per share, with each share sold together with a warrant according to the footnote.
Olivier also acquired 114,545 warrants, each exercisable at $3.025 per common share and expiring on April 27, 2031. Following these transactions, he directly holds 81,818 common shares and 114,545 warrants, reflecting a net addition of 196,363 share-equivalents to his position.
NewcelX Ltd. director Samuel Olivier reported open-market purchases of both common shares and warrants. He bought 81,818 common shares of NewcelX at $2.75 per share, with each share sold together with a warrant according to the footnote.
Olivier also acquired 114,545 warrants, each exercisable at $3.025 per common share and expiring on April 27, 2031. Following these transactions, he directly holds 81,818 common shares and 114,545 warrants, reflecting a net addition of 196,363 share-equivalents to his position.
NewcelX Ltd. furnished a Form 6-K featuring an updated corporate and investor presentation that elevates its Type 1 Diabetes flagship program, NCEL-101, as the core value driver. The program uses enriched stem-cell-derived islets as scalable cell replacement therapy.
The materials describe integrating NewcelX’s islet replacement platform with Eledon Pharmaceuticals’ investigational anti-CD40L antibody tegoprubart to support durable graft survival and pursue a potential functional cure for Type 1 Diabetes. The presentation also outlines a broader pipeline in diabetes and CNS disorders, including AstroRx for ALS and the DOXA orexin agonist platform.
NewcelX Ltd. furnished a Form 6-K featuring an updated corporate and investor presentation that elevates its Type 1 Diabetes flagship program, NCEL-101, as the core value driver. The program uses enriched stem-cell-derived islets as scalable cell replacement therapy.
The materials describe integrating NewcelX’s islet replacement platform with Eledon Pharmaceuticals’ investigational anti-CD40L antibody tegoprubart to support durable graft survival and pursue a potential functional cure for Type 1 Diabetes. The presentation also outlines a broader pipeline in diabetes and CNS disorders, including AstroRx for ALS and the DOXA orexin agonist platform.
NewcelX Ltd. announced a private placement financing with accredited investors, selling 490,907 common shares (or pre-funded warrants) at $2.75 per share, a 30% premium to the prior closing price, and issuing common warrants to purchase up to 687,270 shares at an exercise price of $3.025 per share.
The transaction is expected to provide gross proceeds of $1.35 million, with an additional approximately $2.1 million possible from full cash exercise of the warrants. NewcelX plans to use the proceeds, alongside its previously announced $25 million equity line, to advance NCEL-101, its lead stem-cell-based therapy program for Type 1 Diabetes, as well as other pipeline programs, working capital and general corporate purposes.
The offering is expected to close on or about April 15, 2026, subject to customary closing conditions, and the securities are being issued under Section 4(a)(2) and Rule 506(b) of Regulation D, with a commitment to file a resale registration statement for the underlying shares.
NewcelX Ltd. announced a private placement financing with accredited investors, selling 490,907 common shares (or pre-funded warrants) at $2.75 per share, a 30% premium to the prior closing price, and issuing common warrants to purchase up to 687,270 shares at an exercise price of $3.025 per share.
The transaction is expected to provide gross proceeds of $1.35 million, with an additional approximately $2.1 million possible from full cash exercise of the warrants. NewcelX plans to use the proceeds, alongside its previously announced $25 million equity line, to advance NCEL-101, its lead stem-cell-based therapy program for Type 1 Diabetes, as well as other pipeline programs, working capital and general corporate purposes.
The offering is expected to close on or about April 15, 2026, subject to customary closing conditions, and the securities are being issued under Section 4(a)(2) and Rule 506(b) of Regulation D, with a commitment to file a resale registration statement for the underlying shares.
NewcelX Ltd. filed a current report describing that it has issued a press release announcing a strategic collaboration with Eledon Pharmaceuticals to advance its NCEL-101 program targeting Type 1 diabetes. The report also states that the first four paragraphs of this press release are incorporated by reference into several existing NewcelX shelf registration statements on Form F-3.
NewcelX Ltd. filed a current report describing that it has issued a press release announcing a strategic collaboration with Eledon Pharmaceuticals to advance its NCEL-101 program targeting Type 1 diabetes. The report also states that the first four paragraphs of this press release are incorporated by reference into several existing NewcelX shelf registration statements on Form F-3.
NewcelX Ltd. reported a peer-reviewed scientific review of Mazindol Immediate-Release/Sustained-Release (IR/SR) published in Clinical Drug Investigation. The company views this publication as independent validation of Mazindol ER’s clinical and mechanistic profile within its Contingent Value Right (CVR) framework.
NewcelX stated it is in advanced discussions with multiple potential partners on licensing or acquisition transactions for Mazindol ER, aiming to optimize terms and enhance value for CVR holders and shareholders. The company highlights over 20 years of research and intellectual property dating back to 2006, positioning Mazindol ER as a differentiated central nervous system asset targeting narcolepsy, ADHD, and substance use disorders.
NewcelX Ltd. reported a peer-reviewed scientific review of Mazindol Immediate-Release/Sustained-Release (IR/SR) published in Clinical Drug Investigation. The company views this publication as independent validation of Mazindol ER’s clinical and mechanistic profile within its Contingent Value Right (CVR) framework.
NewcelX stated it is in advanced discussions with multiple potential partners on licensing or acquisition transactions for Mazindol ER, aiming to optimize terms and enhance value for CVR holders and shareholders. The company highlights over 20 years of research and intellectual property dating back to 2006, positioning Mazindol ER as a differentiated central nervous system asset targeting narcolepsy, ADHD, and substance use disorders.
NewcelX Ltd. furnished a 6-K announcing an updated corporate presentation and investor deck ahead of key spring 2026 investor and partnering conferences, including BIO-Europe Spring in Lisbon. The materials emphasize NewcelX’s primary focus on cell-based therapies for Type 1 Diabetes and its broader platform in metabolic and neurodegenerative diseases.
The updated presentation highlights recent scientific progress, clinical development priorities, and the company’s approach to restoring endogenous insulin production using regenerative medicine. It also introduces several new, internationally recognized members of the Scientific Advisory Board and leadership team, which NewcelX states will strengthen expertise across cell therapy development, translational medicine, clinical strategy, and commercialization.
NLS Pharmaceutics Ltd. is changing its independent auditor because CBIZ CPAs P.C. acquired the attestation business of Marcum LLP. Marcum resigned effective September 17, 2025, and CBIZ was engaged the same day as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with Audit Committee approval.
Marcum’s report on the December 31, 2024 financial statements was unqualified but included an explanatory paragraph about substantial doubt regarding the Company’s ability to continue as a going concern. The Company reports no disagreements with Marcum on accounting or auditing matters and, apart from previously disclosed material weaknesses in internal control over financial reporting, no additional reportable events. The Company also states it did not consult CBIZ on accounting or auditing issues before this engagement.
NLS Pharmaceutics Ltd. furnished a report stating that on September 10, 2025 it issued a press release titled “Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger.” The report indicates that a related SEC registration statement for the proposed merger between NLS Pharmaceutics and Kadimastem has become effective, and the press release describing this development is attached as Exhibit 99.1.